Unproven stem cell-based interventions & harm to existing & future patients
Cell & Gene Therapy Insights 2022; 8(3), 397–401
DOI: 10.18609/cgti.2022.057
Published: 27 March 2022
Editorial
“To address these risks to current and future patients, companies developing SCBIs should work with policymakers and patient advocates to protect clinical research and the reputation of the field.”